UK Regulator Targets Major Gaps in Medicine Safety Research for Women

Female medical researcher reviewing clinical research data in an office, illustrating the UK's efforts to address gaps in women's medicine safety evidence

MEDISEARCHER NEWS

United Kingdom · Women’s health · Medicine safety · 17 November 2026

In brief

  • The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) launched its Women’s Health Programme 2026–2030 on 16 November 2026.
  • An MHRA analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023 found that only 1.1% included pregnant women and 0.6% included breastfeeding women.
  • The programme aims to improve evidence about medicine safety and effectiveness for women throughout their lives.
  • Priorities include more inclusive research, better pregnancy and breastfeeding evidence, stronger safety monitoring and clearer patient information.
  • The initiative also addresses menopause, reproductive health, medical devices and conditions that affect women differently from men.
  • No immediate prescribing rules, medicine approvals or pharmacy access arrangements have changed. The programme establishes regulatory priorities for the coming years.

The UK’s medicines regulator has launched a new programme to address longstanding gaps in evidence about how medicines and medical devices work for women, after revealing that pregnant women were represented in just 1.1% of UK clinical trial applications submitted between 2019 and 2023.

Announced on 16 November 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) Women’s Health Programme 2026–2030 aims to improve clinical research, strengthen medicine safety monitoring, support innovation and give patients clearer information about the treatments they use.

The initiative extends beyond reproductive health. It also considers conditions that affect women disproportionately or differently, including cardiovascular disease, chronic illnesses and conditions associated with ageing.

The announcement does not introduce new prescribing rules or immediately change access to medicines. Instead, it establishes a framework for improving the evidence used in future regulatory and treatment decisions.

What did the MHRA announce?

The MHRA introduced its Women’s Health Programme as part of its wider strategy to reduce health inequalities through better regulation of medicines and medical devices.

The programme covers 2026 to 2030 and identifies four main priorities:

  1. Better evidence and data: Understanding differences in treatment safety and effectiveness between women and men.
  2. Innovation and access: Supporting the development and regulatory assessment of medicines and medical technologies addressing women’s health needs.
  3. Pregnancy and breastfeeding: Strengthening evidence to support treatment decisions during these periods.
  4. Patient involvement and communication: Improving the information available to patients and involving women more consistently in regulatory decision-making.

Rather than focusing only on individual diseases, the regulator wants women’s health considerations to become a more consistent part of how medicines and medical devices are developed, assessed, approved and monitored after reaching patients.

The programme applies to the MHRA’s regulatory responsibilities across the UK and complements separate women’s health strategies and initiatives in England, Scotland, Wales and Northern Ireland.

How underrepresented are pregnant and breastfeeding women in clinical trials?

The MHRA examined 4,616 UK clinical trial applications submitted between 2019 and 2023. Its analysis identified particularly limited representation of pregnant and breastfeeding women.

Only 1.1% of trial applications included pregnant women, while 0.6% included breastfeeding women.

The regulator’s programme also reports that only 33% of trials approved during this period included women of childbearing potential.

These findings illustrate how limited direct clinical evidence can be for populations that may nevertheless need prescription medicines to manage acute or chronic health conditions.

Pregnancy and breastfeeding in UK clinical trials

The following chart illustrates the proportion of clinical trial applications that included pregnant or breastfeeding women during the MHRA’s five-year analysis period.

Major gaps in women’s clinical trial evidence

UK clinical trial applications · 2019–2023 · Total: 4,616

Trials including pregnant women 1.1%
Trials including breastfeeding women 0.6%
Key finding: Fewer than two in every 100 UK clinical trial applications included pregnant women, and fewer than one in every 100 included breastfeeding women.
Source: MHRA Women’s Health Programme 2026–2030, published 16 November 2026. The percentages describe the proportion of clinical trial applications including these populations, not the proportion of individual trial participants. Minimum visible bar widths have been applied for accessibility. Chart: MediSearcher.

These figures matter because medicines may behave differently during pregnancy and breastfeeding.

Physiological changes during pregnancy can affect how medicines are absorbed, distributed, metabolised and eliminated. Some treatments may also pose risks to a developing baby or breastfed infant.

When direct clinical evidence is limited, healthcare professionals may have to make treatment decisions using observational data, information from other patient populations and the known properties of a medicine.

Importantly, limited trial inclusion does not mean that all medicines are unsafe during pregnancy or breastfeeding. It means that direct evidence may be insufficient for some treatments, making individual risk-benefit assessment especially important.

Why the evidence gap can affect medicine safety

Clinical trials help regulators establish whether treatments work and whether their benefits outweigh their risks. However, trial populations do not always reflect everyone who will eventually use a medicine.

Pregnant and breastfeeding women have historically been excluded from many studies because of ethical, practical and safety concerns.

Although these concerns can be legitimate, exclusion also creates a problem: patients and clinicians may lack reliable information when treatment is medically necessary.

The MHRA acknowledges that uncertainty can sometimes contribute to patients avoiding or discontinuing potentially important treatments.

For people managing chronic illnesses, stopping medication without appropriate medical advice can itself carry risks.

The appropriate decision depends on the underlying condition, the specific medicine, the stage of pregnancy or breastfeeding, and the available evidence.

The new programme aims to improve this situation through more inclusive research where appropriate, stronger use of real-world data and clearer communication of known benefits and risks.

What could change for medicines used during pregnancy and breastfeeding?

One of the programme’s most specific commitments concerns evidence generation for medicines used during pregnancy and breastfeeding.

The MHRA plans to explore several approaches:

  • More inclusive research: Developing guidance to help researchers consider pregnant and breastfeeding populations appropriately during medicine development.
  • Real-world evidence: Using information gathered during routine healthcare and post-authorisation monitoring to investigate treatment outcomes.
  • Priority medicine pilots: Testing new evidence-generation approaches with selected products where important gaps exist.
  • Stronger safety monitoring: Using existing regulatory tools to investigate uncertainties that remain after a medicine receives approval.
  • Clearer product information: Improving how available pregnancy and breastfeeding evidence is reflected in official medicine information.

These are planned activities rather than completed regulatory changes.

The MHRA has not announced that particular medicines will automatically become approved for use during pregnancy or breastfeeding.

Nor does the programme mean that established safety warnings will be relaxed. Any future change would need to be supported by appropriate evidence and regulatory assessment.

Could the programme improve menopause treatment and HRT access?

Potentially, although no new hormone replacement therapy (HRT) access decision was announced alongside the programme.

The MHRA highlighted previous regulatory decisions involving low-dose vaginal estradiol products and estriol cream as examples of how medicine reclassification can give patients more convenient access to suitable treatments.

These earlier decisions illustrate an important distinction: a regulator can sometimes improve access to an established medicine by changing its legal supply classification when the available evidence supports doing so.

However, the Women’s Health Programme does not itself reclassify additional HRT products or change current prescribing requirements.

Its broader approach could support future work involving menopause, reproductive health, endometriosis, fertility and other areas where treatment options or supporting evidence remain limited.

Women’s health goes beyond pregnancy and menopause

The MHRA’s strategy explicitly takes a broader view of women’s health than reproductive conditions alone.

It recognises that some diseases affect women more frequently, while others may produce different symptoms, treatment responses or outcomes between women and men.

Examples discussed in the programme include cardiovascular disease and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

One priority is improving the collection and analysis of sex-specific data.

This could help identify differences in medicine effectiveness or adverse reactions that may not be apparent when results are reported only for an entire study population.

The regulator also intends to explore patient-reported outcomes, observational healthcare data and appropriately validated advanced analytical methods.

Over time, stronger evidence could help improve medicine information, treatment discussions and regulatory decisions.

However, the programme has not yet demonstrated improvements in clinical outcomes.

What does this mean for women taking prescription medicines now?

There is no immediate change to existing medicine approvals, prescribing guidance or pharmacy access because of this announcement.

Patients should continue following the instructions supplied with their medicines and seek individual advice from an appropriate healthcare professional when questions arise.

For women who are pregnant, planning pregnancy or breastfeeding, the announcement reinforces the importance of discussing treatment decisions rather than independently stopping prescribed medication.

Useful questions for a healthcare professional may include:

  • What evidence is available about this medicine during pregnancy or breastfeeding?
  • What are the risks of continuing treatment compared with leaving the underlying condition untreated?
  • Are there better-studied alternatives for my circumstances?
  • Does the medicine require additional monitoring?
  • Where can I find reliable, up-to-date patient information?

The appropriate answers depend on the individual treatment and clinical circumstances.

A regulatory programme designed to improve future evidence should not be interpreted as a recommendation to change current medication.

What happens next under the 2026–2030 programme?

The MHRA plans to work with patients, researchers, healthcare professionals, industry and other organisations to implement its priorities.

Important developments to watch include:

  • Publication of new guidance on inclusive clinical research and women’s health evidence.
  • Selection of priority medicines for pregnancy and breastfeeding evidence-generation pilots.
  • Improvements in sex-specific medicine safety monitoring and data analysis.
  • Changes to how pregnancy and breastfeeding information is presented in official medicine documentation.
  • Future regulatory decisions that improve access to appropriately evaluated women’s health treatments.

The regulator also plans to strengthen collaboration with national and international partners and maintain patient involvement as the programme develops.

For patients, the most meaningful future milestones will be those that produce practical changes: clearer medicine safety advice, stronger clinical evidence, revised regulatory information or improved access to appropriate treatments.

Frequently asked questions

What is the MHRA Women’s Health Programme 2026–2030?

It is a UK regulatory programme launched on 16 November 2026 to improve evidence, innovation, safety monitoring and patient information relating to medicines and medical devices used by women.

Why are pregnant women underrepresented in clinical trials?

Pregnant women have historically been excluded from many clinical trials because of ethical, safety and practical concerns. This can leave important gaps in evidence about medicines that may still be needed during pregnancy.

How many UK clinical trials included pregnant women?

According to the MHRA’s analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023, only 1.1% included pregnant women.

How many UK clinical trials included breastfeeding women?

The same MHRA analysis found that 0.6% of clinical trial applications included breastfeeding women.

Does the programme change which medicines are safe during pregnancy?

No. The programme does not immediately change existing medicine safety advice or prescribing recommendations. Its aim is to improve the evidence available for future decisions.

Will the programme make HRT easier to obtain?

No new HRT access changes were announced with the programme. However, improving regulatory evidence and supporting innovation could contribute to future decisions involving menopause treatments and other women’s health medicines.

Does the programme apply throughout the United Kingdom?

Yes. The MHRA is the UK’s medicines and medical devices regulator, and the programme addresses its UK-wide regulatory responsibilities.

Should patients stop medicines if they become pregnant?

Patients should not independently stop or change prescribed medicines because of this announcement. Some conditions require continued treatment during pregnancy, and decisions should be made with an appropriate healthcare professional.

The bottom line

The MHRA’s Women’s Health Programme 2026–2030 is a significant acknowledgement that important gaps remain in the evidence used to assess medicines and medical devices for women.

The finding that pregnant and breastfeeding women were represented in only a small fraction of UK clinical trial applications illustrates one particularly important challenge.

Whether the programme ultimately improves treatment decisions will depend on how its commitments are implemented and whether they produce measurable improvements in evidence, regulation and patient care.

For now, it marks a change in regulatory priorities rather than an immediate change in how patients obtain or use medicines.


Reviewed by: Dr Mattias Hagman, PhD

Editorial review: MediSearcher reviewed the MHRA’s 16 November 2026 announcement and its Women’s Health Programme 2026–2030. Clinical trial inclusion statistics, pregnancy and breastfeeding evidence gaps, proposed regulatory initiatives and existing prescribing arrangements are distinguished from confirmed changes to medicine safety guidance or patient access.

Last reviewed: 17 November 2026

Sources and verification

This article provides general health and regulatory information and does not replace individual medical advice. Decisions about medicines during pregnancy, breastfeeding or treatment for chronic conditions require individual clinical assessment. Patients should not stop, start or change prescribed treatments without advice from an appropriate healthcare professional. Regulatory guidance and access arrangements may change after publication.